An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

NCT05011851 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Neuren Pharmaceuticals Limited